Telomere length predicts for outcome to FCR ch... - CLL Support
Telomere length predicts for outcome to FCR chemotherapy in CLL
You need to be a member of this community to see this post.
Read more about...
19 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)
https://ash.confex.com/ash/2018/webprogram/Paper120779.html
CONCLUSIONS: The combination of...
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine,...
Chemotherapy vs Ibrutinib for CLL Frontline Treatment - Dr Susan O'Brien. 12 to 24% of FCR patients effectively cured 6 years after FCR
Anyone interested in the pros and cons of chemotherapy vs non-chemotherapy treatment should watch...
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
Related Posts
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Response and Survival Rates for FCR and Ibrutinib- Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
- Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Five-year results for the iFCG regimen: first-line treatment of CLL patients with mutated IGHV and without del(17p)/TP53 mutation
